ARHGAP19-SLIT1 readthrough (ARHGAP19-SLIT1)

ARHGAP19-SLIT1 readthrough is a fusion RNA generated from transcriptional read-through between the neighboring ARHGAP19 (Rho GTPase-activating protein 19) and SLIT1 (slit homolog 1) genes on chromosome 10[1][3][4][9]. The resulting transcript is predicted to undergo nonsense-mediated mRNA decay, preventing the formation of a protein product[1][4]. This locus is therefore affiliated with the long noncoding RNA (lncRNA) class rather than a conventional protein, receptor, or enzyme target. While ARHGAP19 and SLIT1 individually have defined molecular and physiological roles, the ARHGAP19-SLIT1 readthrough itself is not recognized as a therapeutic target, nor is it typically associated with drug interactions, mechanisms of action, or biomarker status. It may appear in functional association studies, but these often relate to its parent transcripts or are based on RNA-level features, not protein function. Although "ARHGAP19-SLIT1" includes parts of the names "Rho GTPase-activating protein 19" and "Slit homolog 1," this readthrough is not a protein but an RNA molecule subject to decay, making it inappropriate to classify as a receptor, enzyme, or other standard molecular target[1][4].

Other names

ARHGAP19-SLIT1ARHGAP19-SLIT1 readthroughARHGAP19